Table 3 Adverse events possibly related to pembrolizumab
From: Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Event | Grade 1 | Grade 2 | Grade 3 | Total n = 7(%) |
|---|---|---|---|---|
Pneumonitis | 0 | 0 | 2 | 2 (28.6%) |
Diarrhea | 1 | 0 | 0 | 1 (14.3%) |
Pyrexia | 1 | 0 | 0 | 1 (14.3%) |
Anemia | 1 | 1 | 0 | 2 (28. 6%) |
Neutropenia | 1 | 1 | 0 | 2 (28. 6%) |
Thrombocytopenia | 1 | 0 | 1 | 2 (28. 6%) |
Increased ALT | 0 | 1 | 0 | 1 (14.3%) |
Increased AST | 2 | 0 | 0 | 2 (28. 6%) |